Pharminent · Daily Brief
October 30, 2026
Regulatory & Approvals
Labor Department finalizes PBM fee disclosure rule for employers
The Labor Department finalized a rule requiring pharmacy benefit managers to share a broad swath of fee and compensation data with self-funded employer clients starting in 2027. Employers welcomed the rule, while PBMs called it government overreach.
BioPharma Dive →
HHS policy allows compounding of six unapproved wellness peptides
Health Secretary Robert F. Kennedy Jr. backed a new policy allowing licensed professionals to use six wellness-focused peptides that are not approved by the FDA in compounded medicines.
Pharmaceutical Technology →
EMA’s PRAC starts review of Deanxit at October meeting
The EMA’s Pharmacovigilance Risk Assessment Committee began a review of Deanxit, a fixed-dose combination of flupentixol and melitracen used for depression and anxiety, at its meeting held October 26-29, 2026. Ongoing referrals include flupentixol/melitracen-containing medicines and parenteral iron-containing medicines.
EMA →
Clinical Data
Genmab’s cancer antibody succeeds in phase 3 head and neck trial
Genmab said a recently acquired antibody succeeded in a phase 3 trial in a form of head and neck cancer, with findings suggesting it could become a new treatment standard. The company’s market value rose by more than $7 billion.
BioPharma Dive →
Deals & Partnerships
BioMarin licenses long-acting Fabry enzyme therapy for $70M upfront
BioMarin paid $70 million upfront for rights to a clinical-stage, long-acting subcutaneous enzyme replacement therapy for Fabry disease developed by Hanmi and GC Biopharma.
MedCity News →$BMRN
Ferring to acquire fertility biotech Gameto in $1.38B deal
Ferring agreed to acquire fertility biotech Gameto in a deal worth up to $1.38 billion.
PharmExec →
Sanofi’s CEO says M&A and licensing critical before Dupixent patent loss
Sanofi’s CEO said adding to the company’s pipeline through M&A and licensing will be “critical” as it prepares for generic competition to Dupixent.
Pharmaphorum →$SNY
Business & Finance
Lilly’s Mounjaro and Zepbound top $16B in third quarter
Third-quarter sales of Lilly’s tirzepatide products Mounjaro and Zepbound topped $16 billion, exceeding total revenue for many large pharmaceutical companies.
Pharmaceutical Technology →$LLY
Dren Bio raises $350M for dibotatug late-stage development
Dren Bio closed an oversubscribed $350 million private financing round to advance its lead investigational therapy dibotatug through late-stage clinical evaluation, regulatory submission and potential commercialization. The company said the funds will support pivotal trials of the possible first-in-class therapy for rare blood cancers.
Pharmaceutical Technology →
Aspen Neuroscience raises $140M in Nasdaq IPO
Aspen Neuroscience, a San Diego biotechnology startup developing a cell therapy for Parkinson’s disease, raised $140 million in its IPO.
BioPharma Dive →
Bambusa closes Nasdaq IPO as Corxel pursues SPAC merger
Bambusa Therapeutics completed its Nasdaq IPO, while Corxel is pursuing a public debut through a merger with a blank-check company.
Pharmaphorum →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.